ESMO News

Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy

noreply@esmo.org — Mon, 28 Sep 2026 07:09:00 +00:00

Findings from the TAISHAN-302 study

EMA recommends extension of indications for pirtobrutinib

noreply@esmo.org — Fri, 25 Sep 2026 07:09:00 +00:00

New indication concerns the treatment of adult patients with CLL

ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce

noreply@esmo.org — Thu, 24 Sep 2026 12:09:00 +00:00

ESMO welcomes two recent reports by the European Parliament (EP) that recognise the urgent need to strengthen, support and protect Europe’s cancer workforce.

No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC

noreply@esmo.org — Thu, 24 Sep 2026 07:09:00 +00:00

Findings from the SWOG/NRG S1914 study

FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

noreply@esmo.org — Wed, 23 Sep 2026 09:09:00 +00:00

Evidence for efficacy is based on the results from the PSMAddition study

ESMO Calls on the European Commission to Fund Cancer Research and Allocate Funding of at Least €200 Billion to the 10th EU Framework Programme (FP10) Under the Upcoming EU Long-Term Budget

noreply@esmo.org — Wed, 23 Sep 2026 09:09:00 +00:00

Providing robust EU funding to cancer research is a key requisite for driving the development of innovative cancer treatments, meeting unmet needs of patients with cancer, and supporting the work of medical oncologists in Europe and beyond

How can oncologists keep up with the pace of cancer research?

noreply@esmo.org — Wed, 23 Sep 2026 07:09:00 +00:00

The fact that the field of oncology is becoming more complex is good news, but also presents a challenge: how can clinicians manage the breadth and complexity as they support patients?

Comprehensive genomic profiling with subsequent molecularly guided therapy improves outcomes over platinum-based chemotherapy in previously untreated, unfavourable CUP

noreply@esmo.org — Tue, 22 Sep 2026 07:09:00 +00:00

Updated results after additional follow-up in the CUPISCO study

Tebentafusp continues to provide long-term OS benefit in previously untreated patients with unresectable or metastatic uveal melanoma

noreply@esmo.org — Mon, 21 Sep 2026 07:09:00 +00:00

Findings from the final 5-year analysis of overall survival in the IMCgp100-202 study

ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer

noreply@esmo.org — Fri, 18 Sep 2026 08:09:00 +00:00

ESMO notes the EP report An EU Health Workforce Crisis Plan: Sustainability of Healthcare Systems and Employment and Working Conditions in the Healthcare Sector, adopted on 17 September 2026, and supports its call for the urgent strengthening of Europe’s cancer workforce.

ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer

noreply@esmo.org — Fri, 18 Sep 2026 07:09:00 +00:00

Given that smoking is one of the largest preventable causes of cancer and non-communicable diseases worldwide, there is an urgent need for stronger EU legislation to safeguard human health and discourage people from using tobacco products

EMA recommends extension of therapeutic indications for sacituzumab govitecan

noreply@esmo.org — Fri, 18 Sep 2026 07:09:00 +00:00

New indication concerns a combination with pembrolizumab, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC

Perioperative durvalumab continues to show clinical benefit in patients with resectable stage IIA to IIIB NSCLC

noreply@esmo.org — Thu, 17 Sep 2026 07:09:00 +00:00

Findings from a second planned interim analysis of the AEGEAN study

FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

noreply@esmo.org — Wed, 16 Sep 2026 07:09:00 +00:00

Evidence for efficacy is based on the results from the ARROS-1 study

Perioperative durvalumab plus FLOT improves OS in patients with resectable gastric or GEJ adenocarcinoma

noreply@esmo.org — Tue, 15 Sep 2026 07:09:00 +00:00

Findings from the final overall survival analysis of the MATTERHORN study

Azacitidine-venetoclax prolongs EFS over induction chemotherapy among induction-eligible patients with AML

noreply@esmo.org — Mon, 14 Sep 2026 07:09:00 +00:00

Findings from the PARADIGM study

Two studies provide insights into the biological basis of triple-negative breast cancer

noreply@esmo.org — Fri, 11 Sep 2026 12:09:00 +00:00

The new frontier of cancer neuroscience

noreply@esmo.org — Fri, 11 Sep 2026 11:09:00 +00:00

EMA recommends extension of therapeutic indications for teclistamab

noreply@esmo.org — Fri, 11 Sep 2026 07:09:00 +00:00

New indication concerns a combination with daratumumab for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy

ESMO launches Clinical Trials Funding initiative to optimise cancer care pathways

noreply@esmo.org — Thu, 10 Sep 2026 13:09:00 +00:00

ESMO has launched a new Clinical Trials Funding initiative to support independent academic research aimed at optimising cancer care pathways, reducing treatment burden, and improving patient outcomes worldwide